Endometriosis and the menopause: why the question merits our full attention

Lydia Marie-Scemama 1 , 2 , Marc Even 1 , 2 , Jean Bouquet De La Joliniere 3 ,  and Jean-Marc Ayoubi 4
  • 1 Obstetrics & Gynecology, 40 rue Worth Suresnes, France
  • 2 Foch Hospital, Suresnes, France
  • 3 Université de Fribourg, Fribourg, Switzerland
  • 4 Gynécologie - Obstétrique & Médecine de la Reproduction, Faculté de Paris Ouest UVSQ Hôpital Foch jm, Suresnes, France
Lydia Marie-Scemama
  • Corresponding author
  • Obstetrics & Gynecology, 40 rue Worth Suresnes, France
  • Foch Hospital, Suresnes, France
  • Email
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Marc Even
  • Obstetrics & Gynecology, 40 rue Worth Suresnes, France
  • Foch Hospital, Suresnes, France
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Jean Bouquet De La Joliniere and Jean-Marc Ayoubi
  • Gynécologie - Obstétrique & Médecine de la Reproduction, Faculté de Paris Ouest UVSQ Hôpital Foch jm, Suresnes, France
  • Search for other articles:
  • degruyter.comGoogle Scholar

Abstract

As an estrogen-dependent disease, endometriosis was thought to become less active or regress with the onset of the menopause. However, based on some new data, we are discovering that this pathology can emerge or reappear at this period of life. Clinicians must consider it as a possible cause for cases of pelvic pain, and heavy bleeding. Authors have described a possibility of transformation of the intraperitoneal proliferation into a malignant type with ovarian, bowel and even lung metastasis. The risk of transformation into an ovarian cancer is around 2 or 3%. The role of menopausal hormonal therapy will be discussed as in recurrence in the case of residue existence, especially after incomplete surgery. Is it possible to prescribe hormonal therapy to a menopausal women suffering climacteric symptoms as it could trigger a recurrence of endometriosis and even an increased risk of malignant degeneration? This remains unclear. It is an unresolved therapeutic dilemma; the choice between surgery or medical treatment?

  • [1]

    Sampson JA. Metastatic or embolic endometriosis due to premenstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;3:93–110.

  • [2]

    Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–75.

    • Crossref
    • PubMed
    • Export Citation
  • [3]

    Burney RO, Talbi S, Hamilton AE, Vo KC, Nezhat CR, Lessey BA, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–26.

    • Crossref
    • PubMed
    • Export Citation
  • [4]

    Santulli P, Borghese B, Noel JC, Fayt I, Anaf V, de Ziegler D, et al. Hormonotherapy deregulates prostaglandin-endoperoxidase synthase (PTGS2) expression in endometriotic tissues. J Clin Endocrinol Metab. 2014;99:881–90.

    • Crossref
    • Export Citation
  • [5]

    Santulli P, Chouzenoux S, Fiorese M, Marcellin L, Lemarechal H, Millischer AE, et al. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod. 2015;30:49–60.

    • Crossref
    • PubMed
    • Export Citation
  • [6]

    Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, Marut W, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179:880–9.

    • Crossref
    • PubMed
    • Export Citation
  • [7]

    Ngo C, Nicco C, Leconte M, Chereau C, Arkwright S, VAcher Lavenu MC, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol. 2010;222:148–57.

    • Crossref
    • PubMed
    • Export Citation
  • [8]

    Borghese B, Tost J, de Surville M, Busato F, Letourneur F, Mondon F, et al. Identification of susceptibility genes for peritoneal, ovarian, and deep infiltrating endometriosis using a pool sample-based genome-wide association study. Biomed Res Int. 2015;2015:461024.

  • [9]

    Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet. 2012;44:1355–9.

    • Crossref
    • PubMed
    • Export Citation
  • [10]

    Pagliardini L, Gentilini D, Vigano P, Panina-Bordignon P, Busacca M, Candiani M, et al. An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis. J Med Genet. 2013;50:43–6.

    • Crossref
    • PubMed
    • Export Citation
  • [11]

    Borghese B, Barbaux S, Mondon F, Santulli P, Pierre G, Vinci G, et al. Research resource: genome wide profiling of methylated promoters in endometriosis. Mol Endocrinol. 2010;24:1872–85.

    • Crossref
    • PubMed
    • Export Citation
  • [12]

    Umezawa M, Sakata C, Tanaka N, Tabata M, Takeda K, Ihara T, et al. Pathological study for the effects of in utero and postnatal exposure to diesel exhaust on a rat endometriosis model. J Toxicol Sci. 2011;36:493–8.

    • Crossref
    • PubMed
    • Export Citation
  • [13]

    Bendon CL, Becker CM. Potential mechanisms of postmenopausal endometriosis. Maturitas. 2012;72:214–19.

    • Crossref
    • PubMed
    • Export Citation
  • [14]

    Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–79.

  • [15]

    Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:396–406.

  • [16]

    Tan DA, Almaria MJ. Postmenopausal endometriosis: drawing a clearer clinical picture. Climateric. 2018;21:249–55.

    • Crossref
    • Export Citation
  • [17]

    Haas D, Chvatal R, Reichert B, Rennert S, Shebl O, Binder H, et al. Endometriosis: a premenopausal disease? Arch Gynecol Obstet. 2012;286:667–70.

    • PubMed
    • Export Citation
  • [18]

    Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Human Reprod Update. 2017;23:481–500.

    • Crossref
    • Export Citation
  • [19]

    Soliman NF, Hillard TC. Hormone replacement herapy in women with past history of endometriosis. Climateric. 2006;9:325–35.

    • Crossref
    • Export Citation
  • [20]

    Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. 2009. DOI: .

    • Crossref
    • PubMed
    • Export Citation
  • [21]

    Fedele L, Bianchi S, Raffaelli R, Zanconato G. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Fert Steril. 1989;51:781–5.

  • [22]

    Moen MH, Rees M, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, et al. European Menopause and Andropause Society. EMAS position statement: managing the menopause in women with a past history of endometriosis. Maturitas. 2010;67:94–7.

    • Crossref
    • PubMed
    • Export Citation
  • [23]

    Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20:133–9.

    • Crossref
    • PubMed
    • Export Citation
  • [24]

    Melin A, Sparen P, Perrson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Human Reprod. 2006;21:1237–42.

    • Crossref
    • Export Citation
  • [25]

    Audebert A. Women with endometriosis: are they different from others? Gynecol Obstet Fertil. 2005;33:239–46.

    • PubMed
    • Export Citation
  • [26]

    Chene G. Is endometriosis a pre-cancerous lesion Perspectives Implications Cliniques. Gynécol Obstét Fertilité 2016.

  • [27]

    Inceboz U. Endometriosis after menopause. Womens Health (Lond). 2015;11:711–15.

  • [28]

    Streuli I, Gaitzch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climateric. 2017;20:138–43.

    • Crossref
    • Export Citation
  • [29]

    Polyzos NP, Fatemi HM, Zavos A, Papanikolau EG. Aromatase inhibitors in post menopausal endometriosis. Reprod Biol Endocrinol. 2011;9:90.

    • Crossref
    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Hormone Molecular Biology and Clinical Investigation is dedicated to the provision of data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of diseases, such as endocrine cancers, renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases.

Search